Clinical Trial Update: Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing cabozantinib-s-malate versus sunitinib in untreated locally advanced or metastatic kidney cancer completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Kidney Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)
• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-12-21